FolioLanternBeta
RMDResMed| · Insider ownership research

ResMed| insiders sold $22.3M in the past 12 months. How much of their stake is that?

About 11% overall. As a group they ended with more shares than they started with. These figures leave out Peter Farrell, the largest holder (most holdings were last confirmed in 2020).

Updated Oct 9, 2026 from SEC filings · covers Oct 10, 2025 to Oct 9, 2026
How this comparesMore of their stake sold than at 292 of the 416 other companies we can measure (#125 of 417)See ranking
0
buyers among officers and directors, past 12 months
100%
of sales were under disclosed trading plans, past 12 months
5 of 17
officers and directors sold shares, past 12 months
Recent activity · past 30 days, Sep 10, 2026 to Oct 9, 2026
Oct 7, 2026Michael Farrell sold 5K shares ($1.1M) under a disclosed trading plan. That is 1.0% of the total stake held that day. 5K shares came in from vesting or option exercises the same day, so the holding rose by 0 net.
WhoSharesPrice% of total stakeTotal stake afterTrade dateFiled
Michael Farrell
Chairman and CEO, Director
4,991$226.331.0%482KOct 7, 2026Oct 8, 2026

"% of total stake" is the shares in this event against all the vested shares the person held that day, across every share class and holding entity, after that day's vesting. "n/a" means the person's holdings don't reconcile, or the row is a purchase. "Holdings record incomplete" means more shares were sold than the filings show the person held that day, so a percentage would be wrong.

Is this normal? Less than usual: about half of the 5-year average. 5 insiders sold; the average is 8 a year. Year by year
Latest filing: Filed Oct 8 for a sale on Oct 7. Michael Farrell sold 5K shares ($1.1M) under a disclosed plan. Filing
60 SEC ownership filings in the period · See the evidence

What stands out

Two officers sold shares but ended with larger stakes, because more shares came in than were sold: Michael Farrell (sold 63K, 13% of starting holdings; 90K added) and Michael Rider (sold 150, 1.3% of starting holdings; 3.3K added).Michael Farrell: largest sale, Nov 7, 2025 · Michael Rider: largest sale, Feb 4, 2026

Percentages cover 13 of 17 officers and directors. 4 are left out

i
Left out: Justin Leong (holdings couldn't be fully reconciled); Peter Farrell (most holdings were last confirmed in 2020); Jan De Witte (most holdings were last confirmed in 2021); Aaron Bloomer (held no vested shares at the start).
Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Each bar is 100% of that person's own stake; not comparable between people. The stake is the vested shares held at the start of the period (Oct 9, 2025); the gold part is what they sold.

SoldRest of starting stakeAdded during the period
Michael Farrell
Chairman and CEO, Director
Sold 13%, but 63K shares were added (mostly vesting), so the stake grew
13% · $14.6MDisclosed plan
Peter Farrell
Director
Sold $5.0M (plan status beside the amount). Share of stake not shown: most holdings were last confirmed in 2020. Why
$5.0MDisclosed plan
Brett Sandercock
Chief Financial Officer
9.2% · $2.0MDisclosed plan
Jan De Witte
Director
Sold $646K (plan status beside the amount). Share of stake not shown: most holdings were last confirmed in 2021. Why
$646KDisclosed plan
Michael Rider
Global General Counsel
1.3% · $37KDisclosed plan
Amounts, filings and trading plans for each seller

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planOne dollar scale for every month; the tallest bar is labeled
OctNov 2025: $3.9M under a disclosed plan$3.9MNovDec 2025: $2.0M under a disclosed planDecJan 2026: $2.0M under a disclosed planJanFeb 2026: $2.1M under a disclosed planFebMar 2026: $2.0M under a disclosed planMarApr 2026: $1.8M under a disclosed planAprMay 2026: $1.0M under a disclosed planMayJun 2026: $968K under a disclosed planJunJul 2026: $1.1M under a disclosed planJulAug 2026: $2.8M under a disclosed planAugSep 2026: $1.3M under a disclosed planSepOct 2026: $1.1M under a disclosed planOct

Outside holders, reported separately

Michael Farrell reported no open-market sales in the past 12 months. Large shareholders and the funds or companies that board members represent are not part of management, so they are left out of the figures above.

Details

Common questions

Is the ResMed| CEO selling stock?

Yes. Michael Farrell sold 63K shares ($14.6M, 13% of starting holdings) in the past 12 months, all of it under a trading plan disclosed in the filings.

Why are ResMed| insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 100% of sales by value ran under 10b5-1 trading plans disclosed in the filings. A trading plan schedules sales in advance.

Are any ResMed| insiders buying?

No. Officers and directors reported no purchases in the past 12 months.

How much of their stake did ResMed| insiders sell?

About 11% overall. As a group they ended with more shares than they started with. These figures leave out Peter Farrell, the largest holder (most holdings were last confirmed in 2020). That covers the 12 months to Oct 9, 2026 and counts vested shares reported on SEC Forms 3, 4 and 5, which is not an insider's whole wealth.

The evidence

Who sold5 officers and directors: amount, % of holdings, trading plan
Who soldAmount% of holdingsTrading plan
Michael Farrell
Chairman and CEO, Director
$14.6M
63K shares
13%Disclosed plan
Peter Farrell
Director
$5.0M
21K shares
i
No percentage: most holdings were last confirmed in 2020.
Disclosed plan
Brett Sandercock
Chief Financial Officer
$2.0M
8K shares
9.2%Disclosed plan
Jan De Witte
Director
$646K
2.5K shares
i
No percentage: most holdings were last confirmed in 2021.
Disclosed plan
Michael Rider
Global General Counsel
$37K
150 shares
1.3%Disclosed plan

Sold by a charitable foundation the insider reports: Lisette & Michael Farrell Family Foundation, Lisette and Michael Farrell Foundation, Lissette and Michael Farrell Family Foundation, reported by Michael Farrell. A foundation's shares are not the insider's own stake, so they are left out of the figures above.

The full ownership picture16 of 17 insiders fully reconciled · 17 officers and directors

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

InsiderHeld Oct 9, 2025SoldHeld Oct 9, 2026Still held
Michael Farrell
i
Minor difference of 107 shares. Difference is under 0.5% of holdings. Includes unvested RSUs, amount not disclosed. Shares owned by Lisette & Michael Farrell Family Foundation, Lisette and Michael Farrell Foundation are a charitable foundation's, listed separately and not counted here.
Chairman and CEO, Director
470K−63K482K+2.6%
Vesting, gifts, unvested awards and holding lines for Michael Farrell
+63Kshares vested or exercised
0gifted (net of own trusts)
−15Kwithheld by the company for taxes
none reportedunvested awards, start → end
  • Includes unvested RSUs, amount not disclosed.
  • Shares owned by Lisette & Michael Farrell Family Foundation, Lisette and Michael Farrell Foundation are a charitable foundation's, listed separately and not counted here.
Held throughShare classOct 9, 2025Oct 9, 2026
Direct
includes unvested RSUs, amount not disclosed
ResMed Common Stock467,792479,803
Lisette and Michael Farrell Family TrustResMed Common Stock2,0902,090

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
4,993$146.34Nov 21, 2026$399K
55,468$148.90Nov 16, 2030$4.3M
33,036$249.56Nov 25, 2031$0
33,288$250.52Nov 11, 2032$0

Estimate: options held × ($226.33 − strike price), using the most recent insider trade price on Form 4 (Oct 7, 2026), not a market close.

Reconciliation: minor difference of 107 shares. Difference is under 0.5% of holdings.

Brett Sandercock
i
Minor difference of 40 shares. Difference is under 0.5% of holdings. Includes unvested RSUs, amount not disclosed.
Chief Financial Officer
87K−8K83K96%
Vesting, gifts, unvested awards and holding lines for Brett Sandercock
+2Kshares vested or exercised
0gifted (net of own trusts)
none reportedunvested awards, start → end
  • Includes unvested RSUs, amount not disclosed.
Held throughShare classOct 9, 2025Oct 9, 2026
Direct
includes unvested RSUs, amount not disclosed
ResMed Common Stock86,74583,495

Reconciliation: minor difference of 40 shares. Difference is under 0.5% of holdings.

Justin Leong
!
Holdings couldn't be fully reconciled. Balance changed without a matching transaction, and the footnote does not state the amount: -20,702 shares on Aug 14, 2026 (Direct). See the filing Sales and other transactions for Justin Leong are complete.
Chief Product Officer
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Justin Leong
0shares vested or exercised
0gifted (net of own trusts)
none reportedunvested awards, start → end
  • Includes unvested RSUs, amount not disclosed.

Holdings couldn't be fully reconciled. Balance changed without a matching transaction, and the footnote does not state the amount: -20,702 shares on Aug 14, 2026 (Direct). The balances below are as reported, not verified totals.

Held throughShare classOct 9, 2025Oct 9, 2026
Direct
includes unvested RSUs, amount not disclosed
ReMed Common Stock27,18029,028
Direct
includes unvested RSUs, amount not disclosed
ResMed Common Stock49,73035,489
Peter Farrell
!
Most of this insider's holdings were last confirmed in 2020. Confirmed in the last three years: 51,803 shares. Not confirmed since: 1,044,174 shares, left out of this row. "Still held" is not shown because it would cover only the smaller, confirmed part.
Director
68K−21K52Ksee note
Vesting, gifts, unvested awards and holding lines for Peter Farrell
+11Kshares vested or exercised
0gifted (net of own trusts)
−7.5Kwithheld by the company for taxes
none reportedunvested awards, start → end
  • Includes unvested RSUs, amount not disclosed.
  • Additional holdings last reported more than 3 years ago are shown separately and excluded from totals.
Held throughShare classOct 9, 2025Oct 9, 2026
Direct
includes unvested RSUs, amount not disclosed
ResMed Common Stock68,27351,803

Additional holdings last reported Nov 19, 2020, not confirmed since: 1,044,174 shares. Not included in any total or percentage on this page.

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
1,468$249.56Nov 25, 2031$0
1,331$250.52Nov 11, 2032$0

Estimate: options held × ($226.33 − strike price), using the most recent insider trade price on Form 4 (Oct 7, 2026), not a market close.

Reconciliation: minor difference of -1 share. Difference is under 0.5% of holdings.

Ronald Taylor
i
Includes unvested RSUs, amount not disclosed.
Director
24K025Kno sales
Vesting, gifts, unvested awards and holding lines for Ronald Taylor
0shares vested or exercised
0gifted (net of own trusts)
none reportedunvested awards, start → end
  • Includes unvested RSUs, amount not disclosed.
Held throughShare classOct 9, 2025Oct 9, 2026
Direct
includes unvested RSUs, amount not disclosed
ResMed Common Stock23,69824,771
Kaushik Ghoshal
i
Includes unvested RSUs, amount not disclosed.
Chief Commercial Officer, SaaS
19K019Kno sales
Vesting, gifts, unvested awards and holding lines for Kaushik Ghoshal
0shares vested or exercised
0gifted (net of own trusts)
none reportedunvested awards, start → end
  • Includes unvested RSUs, amount not disclosed.
Held throughShare classOct 9, 2025Oct 9, 2026
Kaushik Ghoshal and Jayati Ghoshal Family TrustResMed Common Stock9,6289,628
Direct
includes unvested RSUs, amount not disclosed
ResMed Common Stock9,8029,802
Richard Sulpizio
i
Includes unvested RSUs, amount not disclosed.
Director
18K018Kno sales
Vesting, gifts, unvested awards and holding lines for Richard Sulpizio
0shares vested or exercised
0gifted (net of own trusts)
none reportedunvested awards, start → end
  • Includes unvested RSUs, amount not disclosed.
Held throughShare classOct 9, 2025Oct 9, 2026
Direct
includes unvested RSUs, amount not disclosed
ResMed Common Stock17,79617,796
Carol Burt
Director
18K019Kno sales
Vesting, gifts, unvested awards and holding lines for Carol Burt
0shares vested or exercised
0gifted (net of own trusts)
none reportedunvested awards, start → end
Held throughShare classOct 9, 2025Oct 9, 2026
Carol Burt Hilliard TrustResMed Common Stock14,89216,660
DirectResMed Common Stock2,8512,156
Michael Rider
i
Minor difference of 105 shares. Small increase from an employee stock purchase plan. Includes unvested RSUs, amount not disclosed. Small increase from an employee stock purchase plan.
Global General Counsel
11K−15013K+12%
Vesting, gifts, unvested awards and holding lines for Michael Rider
0shares vested or exercised
0gifted (net of own trusts)
−1.8Kwithheld by the company for taxes
none reportedunvested awards, start → end
  • Includes unvested RSUs, amount not disclosed.
  • Small increase from an employee stock purchase plan. Filing 1 Filing 2
Held throughShare classOct 9, 2025Oct 9, 2026
Direct
includes unvested RSUs, amount not disclosed
ResMed Common Stock11,32712,718

Reconciliation: minor difference of 105 shares. Small increase from an employee stock purchase plan.

Harjit Gill
Director
9.9K011Kno sales
Vesting, gifts, unvested awards and holding lines for Harjit Gill
0shares vested or exercised
0gifted (net of own trusts)
−38withheld by the company for taxes
none reportedunvested awards, start → end
Held throughShare classOct 9, 2025Oct 9, 2026
DirectResMed Common Stock9,90510,940
Karen Drexler
Director
9.5K011Kno sales
Vesting, gifts, unvested awards and holding lines for Karen Drexler
0shares vested or exercised
0gifted (net of own trusts)
none reportedunvested awards, start → end
Held throughShare classOct 9, 2025Oct 9, 2026
DirectResMed Common Stock9,52910,602

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
2,575$148.90Nov 16, 2030$199K

Estimate: options held × ($226.33 − strike price), using the most recent insider trade price on Form 4 (Oct 7, 2026), not a market close.

Jan De Witte
!
Most of this insider's holdings were last confirmed in 2021. Confirmed in the last three years: 4,261 shares. Not confirmed since: 4,989 shares, left out of this row. "Still held" is not shown because it would cover only the smaller, confirmed part.
Director
5.8K−2.5K4.3Ksee note
Vesting, gifts, unvested awards and holding lines for Jan De Witte
0shares vested or exercised
0gifted (net of own trusts)
−76withheld by the company for taxes
none reportedunvested awards, start → end
  • Additional holdings last reported more than 3 years ago are shown separately and excluded from totals.
Held throughShare classOct 9, 2025Oct 9, 2026
DirectReMed Common Stock5,8064,261

Additional holdings last reported Nov 18, 2021, not confirmed since: 4,989 shares. Not included in any total or percentage on this page.

Desney Tan
i
Includes unvested RSUs, amount not disclosed.
Director
4.9K06Kno sales
Vesting, gifts, unvested awards and holding lines for Desney Tan
0shares vested or exercised
0gifted (net of own trusts)
none reportedunvested awards, start → end
  • Includes unvested RSUs, amount not disclosed.
Held throughShare classOct 9, 2025Oct 9, 2026
Direct
includes unvested RSUs, amount not disclosed
ResMed Common Stock4,9296,002
John Hernandez
i
Includes unvested RSUs, amount not disclosed.
Director
4K05.1Kno sales
Vesting, gifts, unvested awards and holding lines for John Hernandez
0shares vested or exercised
0gifted (net of own trusts)
none reportedunvested awards, start → end
  • Includes unvested RSUs, amount not disclosed.
Held throughShare classOct 9, 2025Oct 9, 2026
Direct
includes unvested RSUs, amount not disclosed
ResMed Common Stock4,0455,118
Christopher DelOrefice
Director
1.4K02.4Kno sales
Vesting, gifts, unvested awards and holding lines for Christopher DelOrefice
0shares vested or exercised
0gifted (net of own trusts)
none reportedunvested awards, start → end
Held throughShare classOct 9, 2025Oct 9, 2026
DirectResMed Common Stock1,3502,423
Nicole Mowad-Nassar
Director
2410777no sales
Vesting, gifts, unvested awards and holding lines for Nicole Mowad-Nassar
0shares vested or exercised
0gifted (net of own trusts)
none reportedunvested awards, start → end
Held throughShare classOct 9, 2025Oct 9, 2026
DirectResMed Common Stock241777

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
1,331$250.52Nov 11, 2032$0

Estimate: options held × ($226.33 − strike price), using the most recent insider trade price on Form 4 (Oct 7, 2026), not a market close.

Aaron Bloomer
i
Includes unvested RSUs, amount not disclosed.
Chief Financial Officer
009.1Kno sales
Vesting, gifts, unvested awards and holding lines for Aaron Bloomer
0shares vested or exercised
0gifted (net of own trusts)
none reportedunvested awards, start → end
  • Includes unvested RSUs, amount not disclosed.
Held throughShare classOct 9, 2025Oct 9, 2026
Direct
includes unvested RSUs, amount not disclosed
ResMed Common Stock09,072

16 of 17 insiders fully reconciled: starting holdings plus reported transactions match ending holdings (12 exactly, 4 with a minor or footnoted difference). For 1 we show sales but not holdings; the ! icon on that row explains why. Percentages cover 13 of 17 officers and directors. Left out: Justin Leong (holdings couldn't be fully reconciled); Peter Farrell (most holdings were last confirmed in 2020); Jan De Witte (most holdings were last confirmed in 2021); Aaron Bloomer (held no vested shares at the start). "Still held" compares ending with starting vested shares; a plus sign means the holding grew.

What explains the selling$22.3M of sales by plan status, purpose, seller and month

Officer and director open-market sales: $22.3M across 94,574 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

Taxes

24,579 shares ($4.3M) were withheld by the company for taxes, which isn't a market sale.

SellerShares soldProceedsUnder a disclosed planShare of totalSales dates
Michael Farrell
Chairman and CEO, Director
63K$14.6M100%66%Nov 7, 2025 to Oct 7, 2026
Peter Farrell
Director
21K$5.0M100%22%Nov 12, 2025 to Sep 2, 2026
Brett Sandercock
Chief Financial Officer
8K$2.0M100%9%Nov 3, 2025 to Apr 1, 2026
Jan De Witte
Director
2.5K$646K100%3%Nov 11, 2025 to Nov 25, 2025
Michael Rider
Global General Counsel
150$37K100%0.2%Dec 1, 2025 to Feb 4, 2026

Sales by month

MonthSale proceedsDisclosed planTo cover taxesNo plan disclosed
Oct 2025$0$0$0$0
Nov 2025$3.9M$3.9M$0$0
Dec 2025$2.0M$2.0M$0$0
Jan 2026$2.0M$2.0M$0$0
Feb 2026$2.1M$2.1M$0$0
Mar 2026$2.0M$2.0M$0$0
Apr 2026$1.8M$1.8M$0$0
May 2026$1.0M$1.0M$0$0
Jun 2026$968K$968K$0$0
Jul 2026$1.1M$1.1M$0$0
Aug 2026$2.8M$2.8M$0$0
Sep 2026$1.3M$1.3M$0$0
Oct 2026$1.1M$1.1M$0$0
Is this normal? Selling year by year5 earlier years to compare with

Less than usual: about half of the 5-year average. 5 insiders sold; the average is 8 a year.

12 months endingShares soldInsiders who soldProceeds
Oct 9, 2026
Latest 12 months
95K5$22.3M
Oct 9, 2025
1 year earlier
163K8$40.4M
Oct 9, 2024
2 years earlier
200K8$42.5M
Oct 10, 2023
3 years earlier
180K9$39.3M
Oct 10, 2022
4 years earlier
186K6$44.6M
Oct 10, 2021
5 years earlier
172K7$39.6M

Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.

Known gaps and uncertainty1 insider whose holdings couldn't be fully reconciled

Justin Leong: holdings couldn't be fully reconciled (difference of -20,702 shares). Balance changed without a matching transaction, and the footnote does not state the amount: -20,702 shares on Aug 14, 2026 (Direct). Filing, Aug 14, 2026

Footnote: "Represents performance-based restricted stock units granted on November 20, 2025. The RSUs were earned on August 14, 2026, when the compensation and leadership development committee certified that the applicable performance metrics were met. RSUs vest 1/3 each year on the anniversary of the grant."

Michael Farrell: minor difference of 107 shares. Difference is under 0.5% of holdings.

Brett Sandercock: minor difference of 40 shares. Difference is under 0.5% of holdings.

Peter Farrell: minor difference of -1 share. Difference is under 0.5% of holdings.

Michael Rider: minor difference of 105 shares. Small increase from an employee stock purchase plan.

Inferred rename: "Pledged shares pursuant to Variable Pre-paid Forward Contract with CSFB" is treated as the same holder as "Pledged in a variable pre-paid forward contract with Credit Suisse First Boston", because the old name was never reported again and the new one opened with the same balance (315,000 shares). Old name, new name

Inferred rename: "Kaylara ATF Straflo" is treated as the same holder as "Kaylara ATF Straflo Pension Fund", because the old name was never reported again and the new one opened with the same balance (3,300 shares). Old name, new name

Inferred rename: "Lissette and Michael Farrell Family Trust" is treated as the same holder as "Lisette and Michael Farrell Family Trust", because the old name was never reported again and the new one opened with the same balance (10,340 shares). Old name, new name

Inferred typo: the share class "ResMed Comon Stock" is treated as the same class as "ResMed Common Stock" on 1 holding line, because the two spellings are nearly identical and each balance carried over exactly. Example (Peter Farrell, 3,662,812 shares): old title, new title

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology1,825 filings from SEC EDGAR, and how we read them

All 1,825 Forms 3, 4 and 5 filed for ResMed| (SEC CIK 943819) from Nov 7, 2002 to Oct 8, 2026, retrieved from SEC EDGAR on Oct 9, 2026. Prices are the ones reported in each filing, often weighted averages. 19 older filings exist only on paper and could not be read.

Probable 2-for-1 stock split on or before Nov 17, 2005 (first filing that shows post-split balances). Splits aren't reported as transactions; 6 holding lines changed by exactly this ratio, so earlier share counts are restated.

Probable 2-for-1 stock split on or before Aug 30, 2010 (split date stated in a footnote). Splits aren't reported as transactions; 16 holding lines changed by exactly this ratio, so earlier share counts are restated.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (24)No filing in 18 months; last reported balances, not in any total
NameLast filedLast reported balance
Robert DouglasJan 3, 2024264,375 shares, last reported balance as of Jan 2, 2024
Lucile BlaiseNov 16, 202310,305 shares, last reported balance as of Nov 16, 2023
David PendarvisJun 30, 202389,729 shares, last reported balance as of Jun 30, 2023
James HollingsheadDec 1, 202176,721 shares, last reported balance as of Dec 1, 2021
RESMED INCNov 22, 202113,823 shares, last reported balance as of Nov 18, 2021
Rajwant SodhiSep 3, 202126,731 shares, last reported balance as of Sep 1, 2021
Richard McHaleAug 17, 202022,982 shares, last reported balance as of Aug 13, 2020
John WarehamNov 5, 201911,300 shares, last reported balance as of Nov 4, 2019
Gary PaceMay 10, 2018508,736 shares, last reported balance as of May 8, 2018
Christopher RobertsOct 3, 20172,255,837 shares, last reported balance as of Sep 29, 2017
Anne ReiserAug 23, 201784,633 shares, last reported balance as of Aug 18, 2017
Donald DarkinAug 17, 201613,684 shares, last reported balance as of Aug 15, 2016
Michael QuinnAug 30, 20132,029,000 shares, last reported balance as of Aug 28, 2013
Stein JacobsenNov 28, 201152,143 shares, last reported balance as of Nov 23, 2011
Kieran GallahueJan 7, 201156,922 shares, last reported balance as of Jan 5, 2011
Donagh McCarthyNov 24, 200848,000 shares, last reported balance as of Nov 20, 2008
Lasse BeijerAug 28, 200851 shares, last reported balance as of Aug 26, 2008
Paul EisenMay 27, 2008No balance on record
Keith SerzenNov 13, 20076,573 shares, last reported balance as of Nov 7, 2007
Adrian SmithFeb 22, 2007No balance on record
Christopher BartlettJul 6, 20054,000 shares, last reported balance as of May 24, 2005
Louis SimpsonNov 15, 2004188,800 shares, last reported balance as of Nov 15, 2004
Walter FlickerAug 15, 2003329,600 shares, last reported balance as of Aug 8, 2003
Klaus ShindhelmAug 12, 2003220,000 shares, last reported balance as of Aug 11, 2003

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.